SCHEMBL29310078

SCHEMBL29310078

CC(C)c1ccc(N2CCN(C)C(=O)C2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.45
MGLL Q99685 1/20 0.43
PIK3CD O00329 1/20 0.41
PANK3 Q9H999 3/20 0.41
MAPT P10636 3/20 0.40
MAPK1 P28482 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 3/20 0.40
TP53 P04637 1/20 0.40
THRB P10828 1/20 0.40
LMNA P02545 2/20 0.39
KDM4E B2RXH2 2/20 0.39
GAA P10253 2/20 0.39
ALOX15 P16050 2/20 0.39
ALOX12 P18054 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5726036 0.83 MAPT (0.56) KMT2AMEN1L3MBTL1MAPTMAPK1
SCHEMBL27372191 0.81 MEN1 (0.45) KMT2AMEN1MAPTLMNAHTT
SCHEMBL15465903 0.79 MAOB (0.46) KMT2AMEN1L3MBTL1MGLLMAPT
SCHEMBL26281033 0.79 DRD2 (0.46) KMT2AMEN1MAPTMAPK1ALDH1A1
SCHEMBL20251137 0.78 MAPT (0.51) KMT2AMEN1L3MBTL1MGLLPANK3
SCHEMBL19105585 0.77 PIM1 (0.46) PANK3
SCHEMBL28699851 0.77 ALDH1A1 (0.62) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL1811119 0.76 CTSC (0.36) PIK3CDALDH1A1
SCHEMBL28719456 0.75 CTSC (0.41) KMT2APIK3CDMAPTALDH1A1KDM4E
SCHEMBL28967198 0.75 CTSC (0.36) KMT2APIK3CDMAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 US disclosed
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF WEE1, WEE2, DCLRE1B KMT2A 1422/4885MEN1 1813/4885L3MBTL1 1375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.